Christopher McCabe

1

Article

1

Comment
Health Canada’s new drug licensing proposal contains no mechanism for making fast-tracked medicines affordable. THE CANADIAN PRESS/Ryan Remiorz

Canada’s misguided changes to drug regulation could fast‑track unproven medications and divert funds from other health needs

Steven G. Morgan, University of British Columbia; Aidan Hollis, University of Calgary; Christopher McCabe, Queen's University Belfast; Matthew Herder, Dalhousie University, and Mike Paulden, University of Alberta

The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.

Contact Christopher for

  • General
  • Media request
  • Speaking request
  • Consulting / Advising
  • Research collaboration
  • Research supervision
Friend of The Conversation
What is this? Become a friend.